

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) July 24, 2002

BECTON, DICKINSON AND COMPANY

(Exact name of registrant as specified in its charter)

<TABLE>		
<S>	<C>	<C>
New Jersey	001-4802	22-0760120
----- (State or other juris- diction of incorporation)	----- (Commission File Number)	----- (IRS Employer Iden- tification Number)
1 Becton Drive, Franklin Lakes, New Jersey		07417-1880
----- (Address of principal executive offices)		----- (Zip Code)

Registrant's telephone number, including area code (201) 847-6800

N/A

(Former name or former addresses if changed since last report.)

Item 5. OTHER EVENTS

On July 24, 2002 the Registrant announced in a press release its results for the third quarter ended June 30, 2002.

A copy of the press release is attached as Exhibit 99.1.

Item 7. Financial Statements. Pro Forma Financial Information and Exhibits.

(c) Exhibits.

Exhibit 99.1 Press release dated July 24, 2002
announcing the financial results for the third quarter
ended June 30, 2002.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY
(Registrant)

By: /s/ Kathleen M. Gibson

Kathleen M. Gibson
Assistant Secretary

Date: July 24, 2002

2

INDEX TO EXHIBITS

<TABLE>
<CAPTION>

Exhibit Number -----	Description of Exhibits -----
<S> 99.1	<C> Press release issued July 24, 2002

</TABLE>

Contact:
- -----

Dean J. Paranicas/Investor Relations - 201-847-7102
Charles A. Borgognoni/Corporate Communications - 201-847-6651

BD ANNOUNCES RESULTS FOR FISCAL THIRD QUARTER

Franklin Lakes, NJ (July 24, 2002) - BD (Becton, Dickinson and Company) (NYSE: BDx) today reported quarterly revenues of \$998 million for the fiscal third quarter ended June 30, 2002, an increase of 6 percent from the same period a year ago.

"We are pleased with our performance, paced by solid increases in sales of our safety-engineered products, prefillable drug delivery devices, and BD Biosciences immunology/cell biology reagents and Discovery Labware products," said Edward J. Ludwig, Chairman, President and Chief Executive Officer. "We remain on track to achieve our full-year performance objectives."

Diluted earnings per share were 44 cents for the third quarter. Included in third quarter earnings per share was a special charge of 4 cents recorded primarily in connection with the previously announced manufacturing restructuring in the BD Medical Systems segment. In addition, operating earnings included one cent of other manufacturing costs related to the restructuring that are reflected in cost of products sold. Excluding the special charge of 4 cents, diluted earnings per share would be 48 cents.

Q3 Segment Results - -----

In the BD Medical Systems segment, worldwide revenues of \$544 million increased 7 percent. Included in BD Medical Systems revenues were U.S. safety-engineered product sales of \$88 million, versus \$66 million in the prior year's quarter. Also contributing to the growth of the segment were sales of prefillable drug delivery devices, which grew 20 percent. The overall growth rate in the segment was offset in part by reduced sales of conventional devices in the U.S. due to the transition to safety-engineered devices and by lower Consumer Health Care sales.

Within Consumer Health Care, recording of sales of diabetes syringes in the U.S. is deferred until these products are sold by the Company's distribution channel partners to their end customers. In determining the amount of sales to be recorded each quarter, the Company relies upon independent sales and inventory data from its distribution channel partners. In the third quarter, one distribution channel partner reported that it held a higher level of inventory than it had previously reported to the Company. Accordingly, reported sales of diabetes syringes were negatively impacted by approximately \$8 million. Sales by distribution channel partners to their end customers increased in line with the Company's expectations in the third quarter.

In the BD Clinical Laboratory Solutions segment, worldwide revenues increased 5 percent to \$298 million. Revenue growth of 11 percent in the Preanalytical Solutions portion of the segment was attributable primarily to U.S. safety-engineered device sales, which were \$57 million, versus \$43 million in the prior year's quarter. These results were partly offset by reduced sales of conventional devices due, in large part, to the transition to safety-engineered devices. In addition, worldwide sales of the Diagnostic Systems portion of the segment declined by 2 percent. As discussed in the second quarter press release, U.S. distributors had stocked inventory in advance of the installation by Diagnostic Systems of a new enterprise resource planning system. This inventory stocking adversely impacted revenue growth in the third quarter.

In the BD Biosciences segment, worldwide revenues grew 3 percent to \$156 million. Revenue growth was driven by strong sales of immunology/cell biology reagents (Pharmingen) and Discovery Labware products, which together represent slightly less than half of BD Biosciences' worldwide revenues. Molecular biology reagent (Clontech) revenues decreased versus the prior year's quarter due to continued weakness in some portions of the molecular biology market, largely due to an industry shift from early stage drug target identification to later stage drug development. In response to these developments, BD Biosciences has adjusted its related workforce and redirected its research and development efforts toward later stage drug development products. Softness in pharmaceutical research and development and related capital spending, coupled with the timing of certain instrument installations that are anticipated to occur in the fourth quarter, resulted in essentially flat revenues from flow cytometry instruments and reagents (Immunocytometry Systems) in the quarter.

Q3 Geographic Results - -----

On a geographic basis, third quarter revenues in the U.S. increased 4 percent to \$532 million. Revenues outside the U.S. of \$466 million grew 7 percent. At constant foreign exchange rates, revenues outside the U.S. grew 9 percent.

Nine-month Results

For the nine-month period ended June 30, 2002, reported revenues were \$2.956 billion, a 7 percent increase over a year ago, or 8 percent at constant foreign exchange rates. Diluted earnings per share for the nine-month period were \$1.29, or \$1.35 excluding the special charges primarily relating to the manufacturing restructuring, and reflect an approximate 7 1/2 cent benefit from the adoption of Statement of Financial Accounting Standards (SFAS) No. 142, "Goodwill and Other Intangible Assets." For the same period in fiscal 2001, diluted earnings per share were \$1.14, before the cumulative effect of an accounting change.

Restructuring and Divestitures

In connection with the manufacturing restructuring, the Company recorded a special charge of approximately \$12 million, or 4 cents per share, in the third quarter. Included in this amount was the reversal of approximately \$4 million of special charges recorded in fiscal 2000, primarily resulting from lower than anticipated employee severance. As expected, ongoing operating results in the third quarter reflect the impact of other manufacturing restructuring costs included in cost of products sold, which reduced earnings per share by approximately one cent. The Company recorded a special charge of approximately \$10 million, or two cents per share, in the second quarter of fiscal 2002 associated with this restructuring program.

On April 8, 2002 the Company entered into a non-binding letter of intent with Aortech International plc ("Aortech") to sell its critical care product line. As previously indicated, several important actions must occur, including the execution of a definitive purchase agreement and the approval of Aortech's Board of Directors and shareholders, before the sale can be completed. Assuming these actions are completed, the Company would record a substantially non-cash loss on sale (pre-tax), currently estimated to be in the \$35 to \$40 million range.

Fiscal 2002 Outlook

The Company continues to expect diluted earnings per share to be approximately \$1.88 for fiscal 2002 and approximately 53 cents for the fourth quarter, excluding the special charges and loss on the potential sale of the Critical Care product line. The following table analyzes the estimated reported earnings per share for fiscal 2002:

<TABLE>

<CAPTION>

	Reported Q1	Reported Q2	Reported Q3	Estimated Q4	Estimated FY02
<S>	<C>	<C>	<C>	<C>	<C>
Diluted EPS before manufacturing restructuring and loss on potential sale of Critical Care product line (A)	\$0.37	\$0.50	\$0.49	\$0.54	\$1.90
Manufacturing restructuring costs (B)	-	-	(\$0.01)	(\$0.01)	(\$0.02)
Diluted EPS before special charges and loss on potential sale of Critical Care product line	\$0.37	\$0.50	\$0.48	\$0.53	\$1.88
Special charges	-	(\$0.02)	(\$0.04)	-	(\$0.06)
Diluted EPS before loss on potential sale of (C) Critical Care product line	\$0.37	\$0.48	\$0.44	\$0.53	\$1.82

</TABLE>

(A) These amounts include the previously announced favorable impact from the elimination of goodwill amortization under SFAS No. 142 of approximately \$0.10 per share for the full year, or \$0.025 per quarter.

(B) Recorded to cost of products sold.

(C) Does not include estimated loss on potential sale of Critical Care product line.

BD is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products. For the fiscal year ended September 30, 2001, BD reported total revenues of \$3.8 billion.

This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding the Company's performance, including future revenues, products and income, or events or developments that the Company expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of the Company and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; uncertainties of litigation; the Company's ability to achieve sales and earnings forecasts, which are based on sales volume and product mix assumptions, to achieve its cost savings objectives, and to achieve anticipated synergies and other cost savings in connection with acquisitions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in the Company's ability to maintain favorable supplier arrangements and relationships; changes in interest or foreign currency exchange rates; delays in product introductions; and changes in health care or other governmental regulation, as well as other factors discussed in this press release and in the Company's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements.

BD's news releases can be found on its website at www.bd.com or through Business Wire at www.businesswire.com. A conference call with analysts regarding this news release will be broadcast live on BD's website at 8:30 a.m. EDT Thursday, July 25, 2002. The conference call will be available for playback on BD's website or at 1-800-945-3063 through the close of business on August 1, 2002.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)

<TABLE>
<CAPTION>

	Three Months Ended June 30,		
	2002	2001	% Change
<S>	<C>	<C>	<C>
REVENUES	\$ 998,460	\$ 943,290	5.8
Cost of products sold	514,071	474,891	8.3
Selling and administrative	253,857	248,709	2.1
Research and development	53,037	53,105	(0.1)
Special charges	11,571	-	NM
TOTAL OPERATING COSTS AND EXPENSES	832,536	776,705	7.2
OPERATING INCOME	165,924	166,585	(0.4)
Interest expense, net	(8,678)	(13,155)	(34.0)
Other income (expense), net	1,313	(367)	NM
INCOME BEFORE INCOME TAXES	158,559	153,063	3.6
Income tax provision	38,834	34,934	11.2
NET INCOME	\$ 119,725	\$ 118,129	1.4

EARNINGS PER SHARE

Basic	\$	0.46	\$	0.46	-
Diluted	\$	0.44	\$	0.44	-

AVERAGE SHARES OUTSTANDING

Basic	258,067	258,086
Diluted	269,011	269,653

</TABLE>

NM - Not Meaningful

See page 3 for Notes to Consolidated Income Statements.

Page 1

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)

<TABLE>
<CAPTION>

	Nine Months Ended June 30,		
	2002	2001	% Change
<S>	<C>	<C>	<C>
REVENUES	\$ 2,956,377	\$ 2,758,657	7.2
Cost of products sold	1,536,966	1,415,547	8.6
Selling and administrative	749,811	725,913	3.3
Research and development	164,588	160,329	2.7
Special charges	21,508	-	NM
TOTAL OPERATING COSTS AND EXPENSES	2,472,873	2,301,789	7.4
OPERATING INCOME	483,504	456,868	5.8
Interest expense, net	(27,088)	(47,717)	(43.2)
Other income (expense), net	189	(5,626)	NM
INCOME BEFORE INCOME TAXES	456,605	403,525	13.2
Income tax provision	108,019	97,533	10.8
INCOME BEFORE CUMULATIVE EFFECT OF CHANGE IN ACCOUNTING PRINCIPLE, NET OF TAX	348,586	305,992	13.9
Cumulative effect, net of tax	-	(36,750)	NM
NET INCOME	\$ 348,586	\$ 269,242	NM

BASIC EARNINGS PER SHARE

Before Cumulative Effect	\$	1.34	\$	1.18	13.6
Cumulative Effect		-		(0.14)	NM

Basic Earnings Per Share	\$	1.34	\$	1.04	NM
--------------------------	----	------	----	------	----

DILUTED EARNINGS PER SHARE

Before Cumulative Effect	\$	1.29	\$	1.14	13.2
Cumulative Effect		-		(0.14)	NM

Diluted Earnings Per Share	\$	1.29	\$	1.00	NM

AVERAGE SHARES OUTSTANDING					
Basic		258,568		256,513	
Diluted		269,734		268,357	

</TABLE>

NM - Not Meaningful

See page 3 for Notes to Consolidated Income Statements.

Page 2

BECTON DICKINSON AND COMPANY
NOTES TO CONSOLIDATED INCOME STATEMENTS
Nine Months Ended June 30, 2002

Fiscal 2002 revenues included hedging costs of approximately \$3.1 million for the third quarter and \$7.0 million for the nine months, compared with \$0.4 million and \$8.6 million, respectively, in fiscal 2001. These costs related to BD's purchased option contracts to hedge a portion of its anticipated sales from the United States to non-U.S. customers. Hedging costs of approximately \$8.1 million for the first six months of fiscal 2001 were recorded in Other Expense under previous accounting guidance. This amount has been reclassified to revenues. Also included in revenues were gains on purchased option and forward contracts recorded in revenues in fiscal 2002 of approximately \$1.3 million for the third quarter and \$4.4 million for the nine months compared with \$4.0 million and \$8.1 million, respectively, in fiscal 2001.

BD adopted the provisions of Securities and Exchange Commission Staff Accounting Bulletin No. 101 "Revenue Recognition in Financial Statements," (SAB 101) in the fourth quarter of fiscal 2001, retroactive to October 1, 2000. Prior year amounts have been restated to reflect this adoption. A complete discussion of this accounting change can be found in BD's 2001 annual report on Form 10-K.

Effective October 1, 2001, BD adopted the provisions of SFAS No. 142, "Goodwill and Other Intangible Assets," which, among other things, eliminates the requirement to amortize goodwill and certain other intangible assets. The Company currently estimates the full year impact to earnings per share to be approximately 10 cents or 2.5 cents per quarter.

Page 3

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

	Three Months Ended June 30,		
	2002	2001	% Change
<S>	<C>	<C>	<C>
BD MEDICAL SYSTEMS			
United States	\$ 272,020	\$ 255,434	6.5
International	272,156	251,984	8.0

TOTAL	\$ 544,176	\$ 507,418	7.2

BD CLINICAL LABORATORY SOLUTIONS					
United States	\$	174,976	\$	168,757	3.7
International		123,054		115,659	6.4

TOTAL	\$	298,030	\$	284,416	4.8

BD BIOSCIENCES					
United States	\$	85,083	\$	84,980	0.1
International		71,171		66,476	7.1

TOTAL	\$	156,254	\$	151,456	3.2

TOTAL REVENUES					
United States	\$	532,079	\$	509,171	4.5
International		466,381		434,119	7.4

TOTAL	\$	998,460	\$	943,290	5.8

</TABLE>

<TABLE>
<CAPTION>

		Nine Months Ended June 30,			
		2002	2001	% Change	

<S>	<C>	<C>	<C>	<C>	
BD MEDICAL SYSTEMS					
United States	\$	791,995	\$	725,949	9.1
International		785,595		741,382	6.0

TOTAL	\$	1,577,590	\$	1,467,331	7.5

BD CLINICAL LABORATORY SOLUTIONS					
United States	\$	540,866	\$	504,161	7.3
International		369,570		352,331	4.9

TOTAL	\$	910,436	\$	856,492	6.3

BD BIOSCIENCES					
United States	\$	250,279	\$	241,164	3.8
International		218,072		193,670	12.6

TOTAL	\$	468,351	\$	434,834	7.7

TOTAL REVENUES					
United States	\$	1,583,140	\$	1,471,274	7.6
International		1,373,237		1,287,383	6.7

TOTAL	\$	2,956,377	\$	2,758,657	7.2

</TABLE>

Page 4

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND MAJOR PRODUCT GROUPS
Three Months Ended June 30,
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

		United States			
		2002	2001	% Change	

<S>	<C>	<C>	<C>	<C>	
BD MEDICAL SYSTEMS					
Medical Surgical	\$	178,631	\$	159,871	11.7
Consumer Health Care		66,676		72,832	(8.5)
Pharmaceutical Systems		19,909		15,772	26.2
Ophthalmic Systems		6,804		6,959	(2.2)

TOTAL	\$	272,020	\$	255,434	6.5

BD CLINICAL LABORATORY SOLUTIONS					
Preanalytical Solutions	\$	97,306	\$	86,896	12.0
Diagnostic Systems		77,670		81,861	(5.1)
TOTAL	\$	174,976	\$	168,757	3.7

BD BIOSCIENCES					
Discovery Labware	\$	26,643	\$	25,304	5.3
Immunocytometry & Reagents:					
Flow Cytometry Instruments & Reagents		27,668		29,379	(5.8)
Molecular Biology Reagents		13,617		15,415	(11.7)
Immunology/Cell Biology Reagents		17,155		14,882	15.3
Total Immunocytometry & Reagents		58,440		59,676	(2.1)
TOTAL	\$	85,083	\$	84,980	0.1

TOTAL UNITED STATES	\$	532,079	\$	509,171	4.5
---------------------	----	---------	----	---------	-----

</TABLE>

<TABLE>
<CAPTION>

	International				
	2002	2001	% Change		
<S>	<C>	<C>	<C>		
BD MEDICAL SYSTEMS					
Medical Surgical	\$	148,457	\$	141,077	5.2
Consumer Health Care		45,361		45,106	0.6
Pharmaceutical Systems		71,210		59,863	19.0
Ophthalmic Systems		7,128		5,938	20.0
TOTAL	\$	272,156	\$	251,984	8.0

BD CLINICAL LABORATORY SOLUTIONS					
Preanalytical Solutions	\$	65,551	\$	59,514	10.1
Diagnostic Systems		57,503		56,145	2.4
TOTAL	\$	123,054	\$	115,659	6.4

BD BIOSCIENCES					
Discovery Labware	\$	16,993	\$	15,189	11.9
Immunocytometry & Reagents:					
Flow Cytometry Instruments & Reagents		38,659		37,417	3.3
Molecular Biology Reagents		4,591		4,449	3.2
Immunology/Cell Biology Reagents		10,928		9,421	16.0
Total Immunocytometry & Reagents		54,178		51,287	5.6
TOTAL	\$	71,171	\$	66,476	7.1

TOTAL INTERNATIONAL	\$	466,381	\$	434,119	7.4
---------------------	----	---------	----	---------	-----

</TABLE>

<TABLE>
<CAPTION>

Total

	2002	2001	% Change
<S>	<C>	<C>	<C>
BD MEDICAL SYSTEMS			
Medical Surgical	\$ 327,088	\$ 300,948	8.7
Consumer Health Care	112,037	117,938	(5.0)
Pharmaceutical Systems	91,119	75,635	20.5
Ophthalmic Systems	13,932	12,897	8.0
TOTAL	\$ 544,176	\$ 507,418	7.2
BD CLINICAL LABORATORY SOLUTIONS			
Preanalytical Solutions	\$ 162,857	\$ 146,410	11.2
Diagnostic Systems	135,173	138,006	(2.1)
TOTAL	\$ 298,030	\$ 284,416	4.8
BD BIOSCIENCES			
Discovery Labware	\$ 43,636	\$ 40,493	7.8
Immunocytometry & Reagents:			
Flow Cytometry Instruments & Reagents	66,327	66,796	(0.7)
Molecular Biology Reagents	18,208	19,864	(8.3)
Immunology/Cell Biology Reagents	28,083	24,303	15.6
Total Immunocytometry & Reagents	112,618	110,963	1.5
TOTAL	\$ 156,254	\$ 151,456	3.2
TOTAL REVENUES	\$ 998,460	\$ 943,290	5.8

</TABLE>

<TABLE>
<CAPTION>

FX Neutral % Growth

	International	Total
<S>	<C>	<C>
BD MEDICAL SYSTEMS		
Medical Surgical	5.9	9.0
Consumer Health Care	1.7	(4.6)
Pharmaceutical Systems	18.4	20.0
Ophthalmic Systems	22.2	9.0
TOTAL	8.5	7.5
BD CLINICAL LABORATORY SOLUTIONS		
Preanalytical Solutions	10.7	11.5
Diagnostic Systems	5.3	(0.9)
TOTAL	8.1	5.5
BD BIOSCIENCES		
Discovery Labware	15.4	9.1
Immunocytometry & Reagents:		
Flow Cytometry Instruments & Reagents	6.1	0.8
Molecular Biology Reagents	1.7	(8.7)
Immunology/Cell Biology Reagents	15.5	15.4
Total Immunocytometry & Reagents	7.4	2.3
TOTAL	9.2	4.1
TOTAL	8.5	6.3

</TABLE>

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND MAJOR PRODUCT GROUPS
Nine Months Ended June 30,
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

	United States		
	2002	2001	% Change
<S>	<C>	<C>	<C>
BD MEDICAL SYSTEMS			
Medical Surgical	\$ 521,253	\$ 452,076	15.3
Consumer Health Care	200,348	214,022	(6.4)
Pharmaceutical Systems	50,827	38,464	32.1
Ophthalmic Systems	19,567	21,387	(8.5)
TOTAL	\$ 791,995	\$ 725,949	9.1
BD CLINICAL LABORATORY SOLUTIONS			
Preanalytical Solutions	\$ 277,118	\$ 249,965	10.9
Diagnostic Systems	263,748	254,196	3.8
TOTAL	\$ 540,866	\$ 504,161	7.3
BD BIOSCIENCES			
Discovery Labware	\$ 72,545	\$ 66,969	8.3
Immunocytometry & Reagents:			
Flow Cytometry Instruments & Reagents	88,078	86,345	2.0
Molecular Biology Reagents	41,243	45,409	(9.2)
Immunology/Cell Biology Reagents	48,413	42,441	14.1
Total Immunocytometry & Reagents	177,734	174,195	2.0
TOTAL	\$ 250,279	\$ 241,164	3.8
TOTAL UNITED STATES	\$ 1,583,140	\$ 1,471,274	7.6

</TABLE>

<TABLE>
<CAPTION>

	International		
	2002	2001	% Change
<S>	<C>	<C>	<C>
BD MEDICAL SYSTEMS			
Medical Surgical	\$ 438,598	\$ 421,410	4.1
Consumer Health Care	136,800	140,707	(2.8)
Pharmaceutical Systems	190,776	162,403	17.5
Ophthalmic Systems	19,421	16,862	15.2
TOTAL	\$ 785,595	\$ 741,382	6.0
BD CLINICAL LABORATORY SOLUTIONS			
Preanalytical Solutions	\$ 188,802	\$ 178,223	5.9
Diagnostic Systems	180,768	174,108	3.8
TOTAL	\$ 369,570	\$ 352,331	4.9
BD BIOSCIENCES			
Discovery Labware	\$ 49,566	\$ 45,124	9.8
Immunocytometry & Reagents:			
Flow Cytometry Instruments & Reagents	123,604	107,684	14.8
Molecular Biology Reagents	13,424	13,518	(0.7)
Immunology/Cell Biology Reagents	31,478	27,344	15.1
Total Immunocytometry & Reagents	168,506	148,546	13.4
TOTAL	\$ 218,072	\$ 193,670	12.6
TOTAL INTERNATIONAL	\$ 1,373,237	\$ 1,287,383	6.7

</TABLE>

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND MAJOR PRODUCT GROUPS
Nine Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

	Total		
	2002	2001	% Change
<S>	<C>	<C>	<C>
BD MEDICAL SYSTEMS			
Medical Surgical	\$ 959,851	\$ 873,486	9.9
Consumer Health Care	337,148	354,729	(5.0)
Pharmaceutical Systems	241,603	200,867	20.3
Ophthalmic Systems	38,988	38,249	1.9
TOTAL	\$ 1,577,590	\$ 1,467,331	7.5
BD CLINICAL LABORATORY SOLUTIONS			
Preanalytical Solutions	\$ 465,920	\$ 428,188	8.8
Diagnostic Systems	444,516	428,304	3.8
TOTAL	\$ 910,436	\$ 856,492	6.3
BD BIOSCIENCES			
Discovery Labware	\$ 122,111	\$ 112,093	8.9
Immunocytometry & Reagents:			
Flow Cytometry Instruments & Reagents	211,682	194,029	9.1
Molecular Biology Reagents	54,667	58,927	(7.2)
Immunology/Cell Biology Reagents	79,891	69,785	14.5
Total Immunocytometry & Reagents	346,240	322,741	7.3
TOTAL	\$ 468,351	\$ 434,834	7.7
TOTAL REVENUES	\$ 2,956,377	\$ 2,758,657	7.2

</TABLE>

<TABLE>
<CAPTION>

	FX Neutral % Growth	
	International	Total
<S>	<C>	<C>
BD MEDICAL SYSTEMS		
Medical Surgical	7.2	11.4
Consumer Health Care	(0.3)	(4.0)
Pharmaceutical Systems	18.5	21.1
Ophthalmic Systems	17.5	2.9
TOTAL	8.5	8.8
BD CLINICAL LABORATORY SOLUTIONS		
Preanalytical Solutions	7.8	9.6
Diagnostic Systems	7.3	5.2
TOTAL	7.5	7.4
BD BIOSCIENCES		
Discovery Labware	14.1	10.7
Immunocytometry & Reagents:		
Flow Cytometry Instruments & Reagents	17.8	10.8
Molecular Biology Reagents	(0.7)	(7.2)

Immunology/Cell Biology Reagents	17.1	15.2

Total Immunocytometry & Reagents	16.0	8.5

TOTAL	15.6	9.0

TOTAL	9.3	8.4

</TABLE>